CSIMarket
 


Redhill Biopharma Ltd   (RDHL)
Other Ticker:  
 
 

RDHL's Operating Income Growth by Quarter and Year

Redhill Biopharma Ltd 's Operating Income results by quarter and year




RDHL Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 42.84 81.14 63.68 43.20
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   42.84 81.14 63.68 43.20



RDHL Operating Income fourth quarter 2022 Y/Y Growth Comment
Redhill Biopharma Ltd reported drop in Operating Income in the fourth quarter 2022 by -47.2% to $ 42.84 millions, from the same quarter in 2021.
The fall in the fourth quarter 2022 Redhill Biopharma Ltd 's Operating Income compares unfavorably to the Company's average Operating Income growth of 9.37%.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Operating Income growth. While Redhill Biopharma Ltd ' s Operating Income meltdown of -47.2% ranks overall at the positon no. 1141 in the fourth quarter 2022.

Explain Operating Income growth


RDHL Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December -47.2 % 27.42 % 47.41 % 9.84 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   -47.2 % 27.42 % 47.41 % -11.64 %

Financial Statements
Redhill Biopharma Ltd 's fourth quarter 2022 Operating Income $ 42.84 millions RDHL's Income Statement
Redhill Biopharma Ltd 's fourth quarter 2021 Operating Income $ 81.14 millions Quarterly RDHL's Income Statement
New: More RDHL's historic Operating Income Growth >>


RDHL Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   -47.2 % 27.42 % 47.41 % -11.64 %




Operating Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #76
Overall #1141

Operating Income Y/Y Growth Statistics
High Average Low
47.41 % 9.37 % -47.19 %
(Dec 31 2020)   (Dec 31 2022)
Operating Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #76
Overall #1141
Operating Income Y/Y Growth Statistics
High Average Low
47.41 % 9.37 % -47.19 %
(Dec 31 2020)   (Dec 31 2022)

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Redhill Biopharma Ltd 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RDHL's IV. Quarter Q/Q Operating Income Comment


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RDHL's IV. Quarter Q/Q Operating Income Comment


Redhill Biopharma Ltd 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
0
12 Months Ending
(Dec 31 2020)
Cumulative Operating Income 12 Months Ending $ 42.84 $ 0.00 $ 81.14 $ 0.00 $ 63.68
Y / Y Operating Income Growth (TTM) -47.19 % - 27.4 % - 47.41 %
Year on Year Operating Income Growth Overall Ranking # 1141 # 0 # 0 # 0 # 1208
Seqeuential Operating Income Change (TTM) -47.19 % - 27.4 % - 47.41 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1141 # 0 # 0 # 0 # 1208




Cumulative Operating Income growth Comment
Redhill Biopharma Ltd showed decline, but improvement compare to trailing twelve month Operating Income decrease in 0. If the fiscal year would end in Dec 31 2022, Redhill Biopharma Ltd 's annual Operating Income rise would be -47.19% year on year to $43 millions.

In the Healthcare sector 75 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 0 to 1141.

Operating Income TTM Q/Q Growth Statistics
High Average Low
47.41 %
9.37 %
-47.19 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 76
Overall # 1141

Operating Income TTM Y/Y Growth Statistics
High Average Low
47.41 %
9.37 %
-47.19 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 76
S&P 500 # 1141
Cumulative Operating Income growth Comment
Redhill Biopharma Ltd showed decline, but improvement compare to trailing twelve month Operating Income decrease in 0. If the fiscal year would end in Dec 31 2022, Redhill Biopharma Ltd 's annual Operating Income drop would be -47.19% year on year to $43 millions.

In the Healthcare sector 75 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 0 to 1141.

Operating Income TTM Q/Q Growth Statistics
High Average Low
47.41 %
9.37 %
-47.19 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 76
Overall # 1141

Operating Income TTM Y/Y Growth Statistics
High Average Low
47.41 %
9.37 %
-47.19 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 76
S&P 500 # 1141




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
RDHL's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for RDHL's Competitors
Operating Income Growth for Redhill Biopharma Ltd 's Suppliers
Operating Income Growth for RDHL's Customers

You may also want to know
RDHL's Annual Growth Rates RDHL's Profitability Ratios RDHL's Asset Turnover Ratio RDHL's Dividend Growth
RDHL's Roe RDHL's Valuation Ratios RDHL's Financial Strength Ratios RDHL's Dividend Payout Ratio
RDHL's Roa RDHL's Inventory Turnover Ratio RDHL's Growth Rates RDHL's Dividend Comparisons



Companies with similar Operating Income drop for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2022
Stryker Corp-0.61%$ -0.611 millions
National Healthcare Corp-1.05%$ -1.050 millions
Utah Medical Products Inc-1.15%$ -1.150 millions
Vaso Corporation-1.36%$ -1.365 millions
Mesoblast Ltd-3.09%$ -3.088 millions
Amgen Inc -3.21%$ -3.212 millions
Amedisys Inc -3.99%$ -3.989 millions
Eli Lilly And Company-4.21%$ -4.214 millions
Ligand Pharmaceuticals Incorporated-4.39%$ -4.389 millions
National Research Corporation-4.91%$ -4.910 millions
Charles River Laboratories International inc -5.21%$ -5.206 millions
Steris Plc-5.98%$ -5.977 millions
Baxter International Inc -7.83%$ -7.833 millions
Sotera Health Company-9.42%$ -9.421 millions
Polypid Ltd -9.87%$ -9.867 millions
Alpha Pro Tech Ltd -10.18%$ -10.178 millions
Qilian International Holding Group Limited-11.98%$ -11.978 millions
Zynex inc -12.74%$ -12.740 millions
Essa Pharma inc -14.14%$ -14.138 millions
Qiagen N v -15.65%$ -15.653 millions
Hca Healthcare Inc -15.73%$ -15.728 millions
Lemaitre Vascular Inc -16.07%$ -16.070 millions
Universal Health Services Inc -16.66%$ -16.664 millions
Teleflex Incorporated-17.08%$ -17.076 millions
Intuitive Surgical Inc -17.30%$ -17.296 millions
Surgery Partners Inc -17.94%$ -17.944 millions
Iqvia Holdings Inc -18.14%$ -18.143 millions
Fresenius Medical Care Ag-18.38%$ -18.385 millions
American Shared Hospital Services-18.40%$ -18.396 millions
Eton Pharmaceuticals Inc -19.18%$ -19.178 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com